| Cover Page - USD ($) $ in Thousands | 12 Months Ended | | |
| Dec. 31, 2023 | Apr. 25, 2024 | Jun. 30, 2023 |
| Document Information [Line Items] | | | |
| Document Type | 10-K/A | | |
| Amendment Flag | true | | |
| Document Period End Date | Dec. 31, 2023 | | |
| Document Fiscal Year Focus | 2023 | | |
| Document Fiscal Period Focus | FY | | |
| Trading Symbol | ALRN | | |
| Entity Registrant Name | Aileron Therapeutics, Inc. | | |
| Entity Central Index Key | 0001420565 | | |
| Current Fiscal Year End Date | --12-31 | | |
| Entity Well-known Seasoned Issuer | No | | |
| Entity Voluntary Filers | No | | |
| Entity Current Reporting Status | Yes | | |
| Entity Interactive Data Current | Yes | | |
| Entity Filer Category | Non-accelerated Filer | | |
| Entity Small Business | true | | |
| Entity Emerging Growth Company | false | | |
| Entity Shell Company | false | | |
| ICFR Auditor Attestation Flag | false | | |
| Entity Common Stock, Shares Outstanding | | 16,868,480 | |
| Entity Public Float | | | $ 6,587,576 |
| Entity File Number | 001-38130 | | |
| Entity Tax Identification Number | 13-4196017 | | |
| Entity Address, Address Line One | 12407 N. Mopac Expy | | |
| Entity Address, Address Line Two | Suite 250 #390 | | |
| Entity Address, City or Town | Austin | | |
| Entity Address, State or Province | TX | | |
| Entity Address, Postal Zip Code | 78758 | | |
| City Area Code | 737 | | |
| Local Phone Number | 802-1989 | | |
| Entity Incorporation, State or Country Code | DE | | |
| Document Annual Report | true | | |
| Document Transition Report | false | | |
| Title of 12(b) Security | Common Stock, $0.001 par value | | |
| Security Exchange Name | NASDAQ | | |
| Document Financial Statement Error Correction [Flag] | false | | |
| Amendment Description | This Amendment No. 1 on Form 10-K/A (this “Amendment”) is filed with respect to our Annual Report on Form 10-K for the year ended December 31, 2023 (the “Original Filing”), filed with the Securities and Exchange Commission (the “SEC”) on April 15, 2024. We are filing this Amendment solely for the purpose of including the information required by Part III of Form 10-K, which information was omitted from the Original Filing in reliance on General Instruction G(3) to Form 10-K, which permits the information required by Part III of Form 10-K to be incorporated by reference from a registrant’s definitive proxy statement if it is filed with the SEC no later than 120 days after the fiscal year end. However, we do not intend to file a definitive proxy statement for our 2024 annual meeting of stockholders within 120 days of the end of our fiscal year ended December 31, 2023. Accordingly, this Amendment is being filed solely to (i) provide the information required by Items 10 through 14 of Part III of the Original Filing, and (ii) delete the reference on the cover page of the Original Filing to the incorporation by reference of portions of our definitive proxy statement into Part III of the Original Filing. In addition, as required by Rule 12b-15 under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), new certifications by our principal executive officer and principal financial officer are filed herewith as exhibits to this Amendment pursuant to Rule 13a-14(a) or 15d-14(a) of the Exchange Act. This Amendment speaks as of the date of the Original Filing and, except as described above, this Amendment makes no changes to the Original Filing. This Amendment does not amend, update or change the financial statements or any other information presented in the Original Filing and does not otherwise reflect events occurring after the date of the Original Filing. Accordingly, this Amendment should be read in conjunction with our filings with the SEC subsequent to the filing of the Original Filing. On November 11, 2022, we effected a 1-for-20 reverse stock split of our issued and outstanding common stock. As a result of the reverse stock split, every 20 shares of our common stock issued and outstanding were converted into one share of common stock, without any change in the par value per share. No fractional shares were issued in connection with the reverse stock split. Stockholders who would otherwise have been entitled to a fractional share of our common stock were instead entitled to receive a proportional cash payment. Unless otherwise indicated, all historical share and per share amounts in this Amendment have been adjusted to reflect the reverse stock split. Proportionate adjustments were made to the per share exercise price and the number of shares of common stock that may be purchased upon exercise of outstanding stock options, and the number of shares of common stock reserved for future issuance under our 2006 Equity Incentive Plan, as amended, our 2016 Stock Incentive Plan, our 2017 Stock Incentive Plan, our 2021 Stock Incentive Plan, and our 2017 Employee Stock Purchase Plan. Unless indicated otherwise, throughout this Amendment, references to “Aileron,” “the Company,” “we,” “us” and “our” refer to Aileron Therapeutics, Inc. and its subsidiaries, except where the context otherwise requires or indicates. Aileron and the other trademarks or service marks of Aileron appearing in this Amendment are the property of Aileron. All other trademarks, service marks or other trade names appearing in this Amendment are the property of their respective owners. | | |
| Auditor Name | Marcum LLP | | |
| Auditor Location | New York, NY | | |
| Auditor Firm ID | 688 | | |
